ImmuNextImmuNext
  • Home
  • About Us
  • Partnered Assets
  • Latest News
  • Team
  • Careers
  • Contact Us
  • No menu assigned!
 

Developing novel immunotherapies for autoimmune disease and cancer

ImmuNext's anti-CD40L antagonist enters Sanofi-led Phase 2 trial NCT04572841

Learn about our other immunotherapy assets.

Site Map

  • About Us
  • Careers
  • Contact Us
  • FCOI Policy
  • Home
  • Latest News
  • Partnered Assets
  • Team

Contact Us

ImmuNext Inc.

1 Medical Center Drive
Lebanon, NH 03756

Email: info@ImmuNext.com

© 2021 ImmuNext. All Rights Reserved, ImmuNext Inc.

  • Home
  • About Us
  • Partnered Assets
  • Latest News
  • Team
  • Careers
  • Contact Us